Sermorelin

Overview

Sermorelin (also known as GRF 1-29 or GHRH(1-29)NH₂) is a synthetic peptide consisting of the first 29 amino acids of the 44-amino-acid native human growth hormone releasing hormone (GHRH). These 29 residues represent the biologically active fragment — the minimum sequence required for full GHRH receptor binding and activation.

Sermorelin holds a unique position among growth hormone secretagogues due to its regulatory history. It received FDA approval twice:

• Geref Diagnostic (1997) — approved for evaluating pituitary GH secretory capacity in suspected GH deficiency
• Geref (sermorelin acetate for injection) — approved for the treatment of idiopathic growth hormone deficiency in children with documented growth failure

Sermorelin was voluntarily withdrawn from the market in 2008, not due to safety concerns, but for commercial reasons related to manufacturing difficulties and competition from recombinant GH products. This withdrawal is frequently mischaracterized in community discussions as indicating a safety problem — an important misconception to address.

Despite its market withdrawal, Sermorelin continues to be prescribed off-label by anti-aging and regenerative medicine clinics in the United States, compounded by specialty pharmacies. It remains one of the most commonly prescribed peptides in the clinical anti-aging setting.

Amino Acid Sequence

Sermorelin corresponds to the first 29 amino acids of native GHRH(1-44):

Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂

• Molecular formula: C₁₄₉H₂₄₆N₄₄O₄₂S
• Molecular weight: 3,357.9 g/mol
• CAS Number: 86168-78-7

Key structural notes:

• The sequence is identical to native GHRH(1-29) with C-terminal amidation
• Methionine at position 27 is susceptible to oxidation, reducing biological activity (this vulnerability is addressed in CJC-1295 no DAC by substituting leucine)
• Asparagine at position 8 is prone to deamidation, another stability concern addressed in modified analogs
• These stability limitations are the primary reason newer GHRH analogs such as Mod GRF 1-29 were developed

Mechanism of Action

GHRH Receptor Agonism

Sermorelin binds to the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary gland with the same binding affinity as full-length GHRH(1-44). Receptor activation initiates:

• Coupling to Gs protein and activation of adenylyl cyclase
• Elevation of intracellular cyclic AMP (cAMP)
• Activation of protein kinase A (PKA)
• Phosphorylation of CREB (cAMP response element-binding protein)
• Transcription of the GH1 gene and synthesis of new growth hormone
• Priming and release of GH-containing secretory vesicles

Pituitary Trophic Effects

An important distinction between GHRH analogs like Sermorelin and exogenous GH administration is the trophic effect on the pituitary. Chronic Sermorelin administration has been shown to:

• Maintain and potentially restore somatotroph cell mass
• Preserve the physiological feedback loop between GH, IGF-1, and somatostatin
• Produce GH release in a pulsatile pattern that mirrors natural secretion

In contrast, exogenous GH administration suppresses endogenous GH production through negative feedback, potentially leading to pituitary somatotroph atrophy with prolonged use.

Somatostatin Sensitivity

Sermorelin's GH-releasing effect is subject to somatostatin inhibition. When somatostatin tone is high (post-meal, during certain phases of the ultradian GH rhythm), the GH response to Sermorelin is blunted. This is why:

• Fasting administration produces better results
• Combination with GHRPs (which suppress somatostatin) enhances the response
• Timing relative to natural GH pulse troughs is considered important

Sleep-Related GH Augmentation

When administered before sleep, Sermorelin amplifies the naturally occurring slow-wave sleep (SWS)-associated GH pulse. This is considered one of the most physiologically aligned applications, as the largest natural GH pulse occurs during early SWS.

Research Summary

Pharmacokinetics

• Half-life: 10–20 minutes (significantly shorter than CJC-1295 no DAC's ~30 minutes)
• Onset of action: GH elevation within 5–10 minutes
• Peak GH levels: 15–30 minutes post-injection
• Duration of GH pulse: 1–2 hours
• Route: Subcutaneous injection (standard); intravenous (diagnostic)
• Bioavailability: Good subcutaneous bioavailability, though limited by rapid enzymatic degradation
• Degradation: Susceptible to dipeptidyl peptidase IV (DPP-IV) cleavage at position 2, trypsin-like cleavage, and methionine oxidation
• Food interaction: GH response blunted by food intake; administer fasted

The short half-life is Sermorelin's primary pharmacokinetic limitation compared to newer GHRH analogs. CJC-1295 no DAC (Mod GRF 1-29) was specifically designed to address this through four amino acid substitutions that improve protease resistance.

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Reconstitution

Dosing Schedule

Syringe Measurements (U-100 insulin syringe)

Cycle Guidelines

• Cycle length: 3-6 months (extended protocols up to 12+ months in clinical settings)
• Route: Subcutaneous injection
• Timing: Bedtime to leverage natural nocturnal GH pulse
• Titration: Increase by ~100 mcg every 1-2 weeks
• Injection sites: Rotate between abdomen, thighs, and upper arms

Common Discussion Topics

1. Sermorelin vs. CJC-1295 no DAC — The most common comparison. CJC-1295 no DAC is generally considered the superior GHRH analog due to its improved stability and longer half-life. However, Sermorelin's FDA history gives it a clinical legitimacy that CJC-1295 lacks.

2. Anti-aging clinic prescriptions — Sermorelin is one of the most commonly prescribed peptides in the anti-aging medicine space, often compounded by specialty pharmacies and prescribed for age-related GH decline (a condition sometimes termed "somatopause").

3. Market withdrawal misconceptions — The 2008 voluntary withdrawal is frequently misunderstood. Sermorelin was withdrawn due to manufacturing and commercial considerations, not safety signals.

4. Pediatric vs. adult applications — While FDA-approved for pediatric GH deficiency, off-label adult use for anti-aging is the primary current application.

5. Combination protocols — Sermorelin + Ipamorelin or Sermorelin + GHRP-2 combinations are discussed, though CJC-1295 no DAC has largely replaced Sermorelin as the preferred GHRH component.

6. Compounding pharmacy variability — Quality and potency of compounded Sermorelin products vary between pharmacies, a topic of ongoing community concern.

Related Compounds

• CJC-1295 — a modified GHRH analog with superior stability; has largely supplanted Sermorelin in research protocols
• Ipamorelin — a selective GHRP commonly paired with GHRH analogs for synergistic GH release
• GHRP-6 — a potent GHRP with appetite-stimulating effects; used in early Sermorelin combination studies
• GHRP-2 — the most potent GHRP by GH output; an alternative GHRP for combination protocols
• Tesamorelin (Egrifta) — an FDA-approved GHRH analog (for HIV-associated lipodystrophy) with improved stability over Sermorelin
• Somatorelin — the generic name for synthetic GHRH(1-44); full-length version of the same molecule